Independent Peptide Vendor Public Research

Peptide Certify is an independent reference site. We do not buy, sell, broker, or recommend peptide products, and no vendor can pay for coverage. Vendor articles on this site compile publicly available information: published third-party laboratory test results, archived community discussion, regulatory correspondence such as FDA warning letters, company registration records, and the vendor's own published COA practices.

Each claim in a vendor article is graded by evidence tier: peer-reviewed or regulatory documents first, named third-party laboratory results second, archived community discussion third, and unverified anecdote last — and always labeled as such. Where public information is thin, the article says so plainly rather than padding with speculation.

The COA is the primary public artifact of a peptide vendor's quality system. Credibility checks: is the document batch-specific; does the stated molecular weight match the theoretical mass of the sequence; is the HPLC method documented; are chromatograms included rather than just a number; and is the analysis date plausible relative to the purchase date.

Template COAs — identical purity figures across batches, missing batch numbers, or methods that change when questions are asked — are the single most reliable public red flag. The full field-by-field method is in our characterization and testing pillar.

Public, verifiable checkpoints outperform opinions. Does the vendor publish batch-specific COAs with chromatograms? Do independent third-party test results for their batches exist in public archives, and are the results consistent over time? How does the vendor respond publicly to failed or disputed tests? Is the company transparent about where products ship from and how they are stored?

These are information questions. Answering them does not require trusting anyone's marketing — only reading documents. Our cluster applies the same checklist to every vendor, including Nexaph, Swisschems, and the full public-research index linked at the end of this page.

Community discussion is evidence, but weak evidence unless read carefully. Reliable community signals are specific, dated, and reproducible: a posted third-party lab report with a batch number beats a hundred unsourced opinions. Weight discussions that show original documents, and discount purely affective reviews ("great product") that cannot be checked.

Remember that community data has known distortions: selection bias, vendor-affiliated accounts, and outdated information. The GLP-1 forum discussion overview shows how we label this tier of evidence.

The recurring public red flags: COAs without methods or batch numbers; purity claims unsupported by any chromatogram; third-party tests that cannot be located or that the community has shown to be mismatched to the batch; aggressive affiliate marketing; a pattern of rebranding after reputational damage; and absence of any verifiable company information.

One red flag is a caution; several together form a pattern. The vendor articles in this cluster document the pattern, not just the flags, for each company we cover from public sources.

This cluster compiles our public-research summaries: Peptide Crafters, Nexaph, Mob Biotech, the Peptide Sciences shutdown record, Paramount, Finrick testing data, Planet Peptide, Profound Aminos, Cellex, G5K, Peptides and Proteins Lab 34, Ozptides, Petratide Science, Thera 35, Peptira, Onyx Research, Priority Meds, OrderlyMeds, Lumine Organic, Alpha Labs, Peptides Skye, Skye Labs, Swisschems, Modern Aminos, hydrolyzed collagen suppliers, MNM, Simple Peptides Co, and others — each graded on the same public-evidence scale, each linking back to this pillar.

The same grading scale runs through every vendor article on this site. Tier 1: regulatory and court documents — FDA warning letters, enforcement actions, company filings — carrying legal weight and public verifiability. Tier 2: named third-party laboratory results with batch traceability, including community testing programs that document chain of purchase. Tier 3: archived community discussion with dates and specifics — informative for patterns, never for single claims. Tier 4: unsourced anecdote, used only when labeled, and never load-bearing.

The scale's purpose is not scoring vendors but disciplining us: an article may only be as confident as its highest tier. A vendor with rich Tier 1 material reads differently from one with only forum threads, and that difference is itself the finding — documented precisely, in the article, where you can check it.

The strongest public data source in this market is the community testing program: participants pool funds, purchase samples at retail through ordinary channels, and ship them unopened to an accredited independent laboratory for HPLC and mass-spec analysis. The lab never knows the vendor; the purchase lot is documented; results post publicly with dates.

Aggregated over time, such archives measure consistency — the property single tests cannot. Their known limits: self-selected sampling (enthusiasts test what they buy), unverifiable chain of custody in some older programs, and results that age as vendors change suppliers or processes. Reading them well means holding the strengths and limits together, which is why our vendor articles cite them as Tier 2 with dates, never as verdicts.

A third-party report deserves the same audit as a COA, plus one more layer. Check the method notes (instrument, column, conditions) as you would any chromatogram. Check the batch linkage: does the report reference a lot that could be matched to a purchase, and is the purchase itself documented? Check the dates: a 2023 result says little about a 2026 batch. And check the scope: most programs assay identity and purity, not sterility, endotoxin, or content — the report measures what it measured.

The extra layer is motive: community programs are usually run by unpaid volunteers with no commercial stake, but not always. Our method notes who funded a program where knowable, and treats undisclosed funding as a red flag on the source, not the vendor.

Regulatory correspondence is the strongest public evidence a vendor's operations can generate, precisely because it is involuntary. An FDA warning letter documents what inspectors actually found, under legal penalty for misstatement; a company registry shows where an entity is registered, who runs it, and when it was formed; enforcement archives show outcomes, not allegations. None of it can be bought, spun, or retracted quietly.

For the research peptide market specifically, regulatory records serve a second function: mapping the boundary of legitimate supply. Custom-synthesis houses operating as chemical vendors look very different in the public record than gray-market sellers, and the difference is visible in what regulators have said to each. Our vendor articles use these records where they exist and say plainly where they do not.

Company registries answer boring, decisive questions: does the entity exist, where is it registered, who are its officers, how old is it, has it been renamed. Boring — and decisive, because several classic vendor patterns are registry-visible: the young company with no history selling "established" products; the renamed entity whose prior name appears in regulatory archives; the shell whose registered address is a mail forwarder.

A thin registry is not proof of anything; many small honest businesses register minimally. But a thin registry combined with a thin COA record and an aggressive affiliate program forms a pattern, and patterns are what this pillar documents. The Peptide Sciences shutdown record shows the method applied to a company whose public footprint is unusually well documented.

Gray-market vendors follow recognizable life cycles: rapid growth on community goodwill, a reputational episode (failed test, dispute, seizure), a quiet rename or restart under a new brand, and continuation with a fresh reputation ledger. The public record of each stage is checkable: archives of the old domain, regulatory letters under the old name, community discussion with dates, and registry entries connecting entities.

This matters for research because documentation does not survive a rebrand — the new brand's COA history starts at zero even when the operators do not. Our cluster treats rebrand patterns as historical facts to document, not accusations: where public evidence shows continuity, we cite it; where it does not, we note the absence.

A large fraction of public "vendor review" content is commercial: affiliate pages ranking the sites that pay them, YouTube reviews with discount codes, subreddit posts from accounts that only post about one brand. Detection is mechanical: affiliate disclosure lines, discount codes, links with tracking parameters, review histories spanning a single brand, and rankings that reshuffle when sponsorship changes.

None of this makes a review wrong — it makes it an advertisement, which belongs in the evidence stack as marketing material, not testimony. This is why our editorial policy accepts no affiliate placement: the easiest disclosure rule is not to have the conflict at all, and the easiest way to trust a ranking is to know nobody paid for it.

Our vendor articles improve through public submissions: third-party test reports with batch linkage, regulatory letters, registry documents, dated archive captures. Submissions go to [email protected] with the source identified and, ideally, a link or scan; we verify, grade by tier, and update the relevant article with a dated change note.

Two rules govern submissions: we do not accept non-public information (private disputes, hearsay, screenshots of private messages), and we do not remove accurate public records on request. The contact page carries the same terms; corrections always receive priority over new material.

The full method, condensed: start from the document you actually hold — a COA, a third-party report — and audit it field by field. Then widen: batch consistency across public COAs, third-party coverage over time, regulatory and registry records, community discussion weighted by specificity and date. Record everything in dated notes; patterns only emerge from records, and rebrand detection only works when your notes are older than the rebrand.

The workflow's output is not a verdict but a documented profile: what is publicly known, how strong the evidence is, what is missing. That is the same product our vendor articles deliver — and with the checklist above, you can produce it yourself for any vendor we have not covered.

A vendor's public footprint often shows a structure rather than a factory. Some sellers are manufacturers with in-house synthesis; more are resellers forwarding orders to contract synthesis houses; some are drop-shippers with no laboratory anywhere in the chain, whose only quality system is the supplier's. None of these structures is secret: shipping origins, documentation formats that match known manufacturers, and consistent batch styles across supposedly unrelated storefronts all leak the structure.

Why a researcher cares: quality accountability attaches to whoever measures the product, and in a chain, that party is often invisible to you. A reseller can relay your COA questions upstream — or quietly rewrite the document. The public check is whether the vendor's documents look like the manufacturer's originals or the vendor's own template, and our vendor articles note the distinction where public evidence shows it.

A public-research site collects pressure. Vendors object to documented shutdown records, to third-party test results that predate their current process, to registry facts. Our policy is uniform: we do not remove accurate, dated, public-record material, and we do not alter evidence tiers on request. We do correct genuine errors, promptly, with a visible change note — accuracy is the whole product, and correcting it is maintenance, not concession.

The boundary we hold is between facts and framing. A regulatory letter is a fact; a sentence that reads as an accusation rather than a description is framing, and we fix framing on request. This is also why vendor articles read carefully worded: precise language is not timidity, it is the price of publishing things people would rather were not published.

Honesty about limits is part of the method. Public research cannot tell you how a vendor's current batches will test — it measures history, and history is only correlated with the present. It cannot see into batches never tested, vendors never discussed, or private quality changes. Community archives over-represent popular products and controversy; quiet competence is under-sampled by construction. And every archive ages: a 2024 third-party result describes a 2024 batch, full stop.

These limits define correct use: public research narrows the question — from "who is trustworthy" to "whose documents survive auditing, whose batches test consistently, and whose public record shows patterns worth knowing" — and the final step is always your own batch-specific documentation check. The pillars teach that check; the vendor articles supply the historical record that makes it informed.

A vendor we have not covered, evaluated in twenty minutes of public research. Documents: their site posts COAs with batch numbers and gradient notes — promising; two different products share an identical chromatogram file name — a template flag. Third-party archives: two results, both 2024, both high purity, different batches — consistent but dated. Registries: an LLC, two years old, one officer, a residential-adjacent registered address — thin but not damning. Community: specific, dated praise about shipping speed; one detailed, documented dispute about a mislabeled vial that the vendor publicly resolved.

Profile: promising documentation habits, one serious template flag to resolve, consistent but aging third-party data, a footprint consistent with a small reseller, and a community record showing real dispute resolution. No verdict — a profile with exactly one follow-up question (the chromatogram) that a first order would answer definitively. That is the method working.

Every vendor article in this cluster follows the same six-part structure, so you always know where to look. The public footprint section states what public sources exist and how strong they are. What public information covers lists the checkable facts. The COA credibility checks section applies the field-by-field method from our characterization pillar to this vendor. Third-party testing and community data presents dated external results with their tier. Red flags documents patterns — as facts to record, not reactions. And how we grade this article states the evidence posture and the independence statement.

The fixed structure is deliberate: it makes the articles comparable, makes omissions visible (a section that is short says the public record is short), and makes our method auditable against every page that claims to apply it.